IDH.L Regulatory News (IDH)

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain

31 October 2017

Immunodiagnostic Systems Holdings plc

Directorate Change

Immunodiagnostic Systems Holdings plc ("IDS" or the "Company"), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, today announces that Regis Duval, Chief Executive Officer, has stepped down from his role as a Director of the Company and all associated directorships of IDS with immediate effect. Regis is stepping down for personal reasons in order to spend more time with his family in Luxemburg.

Since his appointment as CEO in March 2017, Regis has initiated several initiatives to halt the decrease in revenues IDS has been experiencing, in particular working on employee engagement across the Company, improving the operations and filling several important management positions. The role of Chief Executive Officer has been taken over by Jaap Stuut with immediate effect. Jaap has been with the Company since 2013, and was previously responsible for the global marketing and corporate development of the Company as well as having the direct sales responsibility for the USA and Brazil. Before this he was responsible for global marketing.

Prior to joining IDS, Jaap worked at SHO Centra for Medical Diagnostics, where he held the position of Chief Operating Officer, responsible for Sales, Marketing & Operations. Additionally he worked at Roche Diagnostics where he held several senior Sales & Marketing roles in the Clinical Medical Diagnostics team. Jaap is a Dutch national and holds an MBA from Bradford University School of Management.

Dr Burkhard Wittek, Non-Executive Chairman of IDS, commented: "IDS would like to thank Regis for his contribution to IDS during the time he spent with us. The improvement in employee engagement achieved in his time is testimony to his leadership skills. He is also leaving us a simplified organization with all key positions filled. We wish him all the best in his family life and future career.

I would like to welcome Jaap as the new CEO. When I became Chairman of the Company, Jaap was a key member of the marketing department. In the years since, he was first promoted to lead the marketing department, then added the corporate development function to his remit, and finally taking on certain direct sales responsibilities.

What IDS now needs more than ever is a strengthening of the sales and marketing capabilities - and that is exactly what Jaap brings to the team. He will continue to focus on spending time in the field with our sales organization, key clients and opinion leaders. I wish him success and look forward to continue the good work and open communication with the Board."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name and age: Jaap Stuut (aged 47).

Mr. Stuut does not currently hold any ordinary shares in Immunodiagnostic Systems Holdings plc.

Current Directorships or Partnerships:

Jaap Stuut Beheer BV 

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Burkhard Wittek, Non-Executive Chairman

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson